Sustained myeloprotection and economic impact of trilaciclib during first-line chemotherapy for extensive-stage small-cell lung cancer: a propensity score-matched real-world cohort study
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background Chemotherapy-induced hematologic toxicity remains a challenge in extensive-stage small-cell lung cancer (ES-SCLC). We evaluated associations between trilaciclib use, hematologic toxicity, cumulative toxicity burden, and supportive care drug-cost offsets. Methods This retrospective study compared first-line platinum–etoposide chemotherapy with or without trilaciclib. Propensity score matching targeted a 1:2 ratio. Matched-set regression, generalized estimating equations, and count and recurrence models assessed patient-level, longitudinal, and cumulative outcomes. Sensitivity analyses assessed residual confounding. Growth factor drug-cost offsets were explored. Results Among 461 screened patients, 135 matched patients (49 trilaciclib, 86 controls) were included. Trilaciclib use was associated with lower grade 3–4 hematologic toxicity (16.3% vs 52.3%; OR, 0.20; P < 0.001), neutropenia (16.3% vs 48.8%; OR, 0.23; P < 0.001), and granulocyte colony-stimulating factor utilization (55.1% vs 82.6%; OR, 0.32; P = 0.003). Cycle-adjusted analyses supported these associations; no significant treatment-by-cycle interactions were detected. Cumulative toxicity burden was lower with trilaciclib (median affected cycles per patient, 0 vs 1; P = 0.003), with fewer recurrent grade 3–4 toxicity events (4.1% vs 20.9%; P = 0.029). Under a four-cycle daily whole-vial costing scenario, estimated trilaciclib costs were RMB 11,184 per patient, with growth factor drug-cost offsets of RMB 380 (95% bootstrap CI, − 147 to 911). Sensitivity analyses yielded directionally consistent estimates. Conclusions Trilaciclib use was associated with lower severe hematologic toxicity, cumulative toxicity burden, and supportive care requirements. Estimated growth factor drug-cost offsets covered only a small proportion of acquisition costs. Comprehensive economic evaluations incorporating broader clinical benefits are warranted.
Source: Research Square
Authors: Wen Chen, Yubingxue Liu, Li Li, Tingxiu Xiang
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236448994
